Literature DB >> 20978877

Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.

Junya Kuroda, Tsutomu Kobayashi, Yasuhiko Tsutsumi, Mio Yamamoto, Muneo Ohshiro, Nana Sasaki, Yuji Shimura, Shinsuke Mizutani, Hisao Nagoshi, Miki Kiyota, Ryuko Nakayama, Hitoji Uchiyama, Yosuke Matsumoto, Shigeo Horiike, Chihiro Shimazaki, Masafumi Taniwaki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20978877     DOI： 10.1007/s12185-010-0709-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  8 in total

1.  Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity.

Authors:  Kai Sun; Danice E C Wilkins; Miriam R Anver; Thomas J Sayers; Angela Panoskaltsis-Mortari; Bruce R Blazar; Lisbeth A Welniak; William J Murphy
Journal:  Blood       Date:  2005-06-16       Impact factor: 22.113

2.  Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.

Authors:  M C Minnema; M S van der Veer; T Aarts; M Emmelot; T Mutis; H M Lokhorst
Journal:  Leukemia       Date:  2008-09-11       Impact factor: 11.528

3.  Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.

Authors:  Benedetto Bruno; Francesca Patriarca; Roberto Sorasio; Daniele Mattei; Vittorio Montefusco; Jacopo Peccatori; Francesca Bonifazi; Maria Teresa Petrucci; Giuseppe Milone; Stefano Guidi; Luisa Giaccone; Marcello Rotta; Renato Fanin; Mario Boccadoro; Paolo Corradini
Journal:  Haematologica       Date:  2006-06       Impact factor: 9.941

4.  Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.

Authors:  Niels W C J van de Donk; Nicolaus Kröger; Ute Hegenbart; Paolo Corradini; Jesus F San Miguel; Hartmut Goldschmidt; Jose A Perez-Simon; Mark Zijlmans; Reinier A Raymakers; Vittorio Montefusco; Francis A Ayuk; Marinus H J van Oers; Arnon Nagler; Leo F Verdonck; Henk M Lokhorst
Journal:  Blood       Date:  2006-04-15       Impact factor: 22.113

5.  Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation.

Authors:  Juan Mateos-Mazon; José-Antonio Pérez-Simón; Olga Lopez; Emiliano Hernández; Jaime Etxebarria; Jésus F San Miguel
Journal:  Haematologica       Date:  2007-09       Impact factor: 9.941

6.  High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.

Authors:  Jean El-Cheikh; Mauricette Michallet; Arnon Nagler; Hugues de Lavallade; Franck E Nicolini; Avichai Shimoni; Catherine Faucher; Mohamad Sobh; Daniela Revesz; Izhar Hardan; Sabine Fürst; Didier Blaise; Mohamad Mohty
Journal:  Haematologica       Date:  2008-02-20       Impact factor: 9.941

Review 7.  Role of autologous and allogeneic stem cell transplantation in myeloma.

Authors:  W I Bensinger
Journal:  Leukemia       Date:  2009-01-29       Impact factor: 11.528

8.  Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.

Authors:  Kai Sun; Lisbeth A Welniak; Angela Panoskaltsis-Mortari; Matthew J O'Shaughnessy; Haiyan Liu; Isabel Barao; William Riordan; Raquel Sitcheran; Christian Wysocki; Jonathan S Serody; Bruce R Blazar; Thomas J Sayers; William J Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.